BillionToOne Reports Strong 2025 Financials with 100% Revenue Growth, Achieves Profitability; Discloses Unremediated Material Weaknesses in Internal Controls

summarizeSummary

BillionToOne, Inc. filed its 2025 Annual Report, confirming robust financial performance with 100% revenue growth and net income of $7.5 million, but also disclosed unremediated material weaknesses in its internal control over financial reporting.

check_boxKey Events

• Strong 2025 Financial Performance Confirmed

  The company reported a 100% increase in revenue to $305.1 million for the year ended December 31, 2025, up from $152.6 million in 2024. It achieved a net income of $7.5 million in 2025, a significant turnaround from a net loss of $41.6 million in 2024. Gross margin improved substantially to 68% in 2025 from 53% in 2024, driven by increased test volumes and higher average selling prices.

• Unremediated Material Weaknesses in Internal Controls

  BillionToOne disclosed that material weaknesses in its internal control over financial reporting remained unremediated as of December 31, 2025. These weaknesses relate to an ineffective control environment, inadequate controls for analyzing and disclosing financial instruments (warrants and debt), and insufficient user access controls for journal entries. Remediation efforts are ongoing in 2026.

• Operational Expansion and Growth Initiatives

  The company expanded its sales force from 137 representatives at the end of 2024 to 231 by the end of 2025, supporting growth in both prenatal and oncology product lines. A new 220,000 square foot laboratory facility in Austin, Texas, is planned to commence operations in 2027/2028, expected to nearly triple current testing capacity.

• Mandatory Debt Tranche Triggered

  BillionToOne is required to sell a $30.0 million tranche of notes prior to March 31, 2026, having met the revenue and gross margin thresholds for this obligation on June 30, 2025. This is part of an existing debt facility with Oberland Capital.

auto_awesomeAnalysis

BillionToOne, Inc.'s 2025 Annual Report on Form 10-K confirms the strong financial performance previously indicated in its recent 8-K filing, showcasing significant revenue growth and a return to profitability. However, the filing also reveals unremediated material weaknesses in the company's internal control over financial reporting, which is a notable concern for investors. These control deficiencies, particularly in the control environment, accounting for financial instruments, and user access, could impact the reliability of future financial reporting and compliance. While the company is actively working on remediation, their persistence as of year-end 2025 presents a governance risk. The operational highlights, such as expanding sales force and planned new facility, underscore growth initiatives, but the internal control issues warrant close monitoring.